Details

Autor(en) / Beteiligte

• Baldewpersad Tewarie, N.M.S.
• van Driel, W.J.
• van Ham, M.
• Wouters, M.W.
• Kruitwagen, R.
• Kruse, A.J.
• Yigit, R.
• van der Aa, M.
• Mens, J.W.
• Stam, T.C.
• Diepstraten, J.
• van der Kolk, A.
• Verhoeve, H.
• Smedts, H.P.M.
• van Haaften-de Jong, A.M.L.D.
• Reesink, N.
• Vos, M.C.
• Ten Cate, A.D.
• Slangen, B.F.M.
• Timmers, P.J.
• Smit, R.A.
• Gaarenstroom, K.N.
• Vencken, P.M.L.H.
• Engelen, M.J.A.
• Verbruggen, M.B.
• Boll, D.
• Briet, J.
• Fons, G.
• Coppus, S.F.P.J.
• Baalbergen, A.
• van Dorst, E.B.L.
• Tjiong, M.Y.
• Roes, E.M.
• Visschers, B.A.J.T.
• Gerestein, C.G.
• Nagel, H.T.C.
• Aalders, A.L.
• Hofman, L.
• Lange, J.
• Ebisch, I.
• de Waard, J.
• van der Plas-Koning, Y.W.C.M.
• Huisman, M.

Titel

Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA)

Ist Teil von

• Gynecologic oncology, 2021-08, Vol.162 (2), p.331-338

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The challenge when performing cytoreductive surgery (CRS) is to balance the benefits and risks. The aim of this study was to report short term postoperative morbidity and mortality in relation to surgical outcome in patients undergoing primary debulking surgery (PDS) or interval debulking (IDS) surgery in the Netherlands. The Dutch Gynecological Oncology Audit (DGOA) was used for retrospective analysis. Patients undergoing PDS or IDS between January 1st, 2015 - December 31st, 2018 were included. Outcome was frequency of postoperative complications. Median time to adjuvant chemotherapy and severity of complications were related to outcome of CRS. Complications with Clavien-Dindo ≥3 were analyzed per region and case mix corrected. Statistical analysis was performed with R.Studio. 1027 patients with PDS and 1355 patients with IDS were included. Complications with re-invention were significantly higher in PDS compared to IDS (5.7% vs. 3.6%, p = 0.048). Complete cytoreduction was 69.7% in PDS and 62.1% IDS, p < 0.001. Time to adjuvant chemotherapy was 49 days in patients with complete CRS and a complication with re-intervention. Regional variation for severe complications showed one region outside confidence intervals. Higher complete cytoreduction rate in the PDS group indicates that the correct patients have been selected, but is associated with a higher percentage of complication with re-intervention. As result, time to start adjuvant chemotherapy is longer in this group. Maintaining a balance in aggressiveness of surgery and outcome of the surgical procedure with respect to severe complications is underlined. Bench marked data should be discussed nationally to improve this balance. •Complications with re-invention were significantly higher in PDS compared to IDS.•Time to start adjuvant chemotherapy is longer in patients with severe complcations.•Regional variation for severe complications is apparent in the Netherlands